What Seretide Treats: Main Uses and Benefits

This combination therapy is indicated for the daily maintenance treatment of Persistent Asthma in patients aged 4 years and older, and for the long-term management of Chronic Obstructive Pulmonary Disease (COPD). It is generally used for patients whose symptoms are generally not adequately managed by an inhaled corticosteroid alone, and may be part of symptomatic management to help support functional stability.

The medication is commonly used across conditions involving recurrent or fluctuating manifestations where supportive symptom management is appropriate. The therapy is relevant for easing symptoms related to recurrent wheezing, shortness of breath, and chronic cough. This approach is relevant for easing symptoms that interfere with daily comfort and assists with maintaining functional stability over time. The goal of this treatment is to help maintain a sense of stability when symptoms are more noticeable. This supports general well-being during symptomatic phases.

---

Quick Fact: Focus on Chronic Airway Symptoms

Category	Description
Primary Indication	Persistent Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Symptoms Eased	Recurrent wheezing, dyspnea, nocturnal/morning chest tightness
Therapeutic Focus	Long-term symptom management and supportive stability
Usage Context	Daily, scheduled maintenance treatment

Regulatory References

1. NIH DailyMed drug label

Seretide (fluticasone propionate/salmeterol) is an inhaled combination medicine intended strictly for regular, maintenance treatment and must not be used for the immediate relief of acute asthma symptoms or an acute attack of breathlessness.

Populations Excluded or Contraindicated

• Allergy Status: Use is contraindicated in patients with a history of hypersensitivity (allergy) to either active ingredient (salmeterol xinafoate, fluticasone propionate) or any excipients, including milk proteins.
• Acute Symptoms: It is formally prohibited for use as a fast-acting rescue medication.

Populations Requiring Caution or Conditional Use

• Age Limits: The medicine is not recommended for use in children under 4 years of age due to insufficient clinical data. Use in children 4 years and older is for regular asthma treatment at specified strengths.
• Comorbidities: Caution is required when prescribing to patients with severe cardiovascular disorders (including heart rhythm abnormalities), thyrotoxicosis, diabetes mellitus (due to rare reports of increased blood glucose), or untreated hypokalaemia.
• Hepatic Status: Data on use in patients with hepatic impairment (liver dysfunction) are not available, implying caution is required.
• Pregnancy and Lactation: Administration during pregnancy should only be considered if the expected benefit to the mother outweighs any possible risk to the foetus or child. A decision to discontinue breastfeeding or discontinue the drug must be made, considering its importance to the mother.

Interactions with Other Medicines and Products

Seretide's official interaction profile is characterized by pharmacokinetic and pharmacodynamic restrictions documented in regulatory labeling. The primary pharmacokinetic caution involves agents that affect the metabolism of the Fluticasone Propionate component.

Pharmacokinetic Interactions

Category	Interaction Outcome
Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole)	Increase systemic exposure to fluticasone propionate due to reduced clearance, raising the risk of systemic corticosteroid effects. Concomitant use with Ritonavir is generally not recommended.

Pharmacodynamic Interactions

Category	Interaction Restriction
Other Long-Acting Beta-2 Agonists (LABAs)	Co-administration is not recommended due to the risk of excessive beta-adrenergic stimulation.
Beta-Adrenergic Blockers	Should be avoided as they may antagonize the bronchodilator effect of the Salmeterol component, potentially causing severe bronchospasm.
MAOIs and Tricyclic Antidepressants	Use with extreme caution due to the potential to potentiate salmeterol's effects on the vascular system.
Non-Potassium-Sparing Diuretics	Use with caution, as they may worsen hypokalemia associated with the beta-agonist.

Population and Non-Drug Interactions

No data are available in official regulatory documents regarding the use of Seretide in patients with hepatic impairment. Grapefruit juice may interact due to its capacity for CYP3A4 inhibition, mirroring the effect of strong drug inhibitors.

Dual Mechanism: Targeting Smooth Muscle and Inflammation

This drug acts through a dual-component mechanism by engaging two distinct receptor systems: the beta2-adrenergic receptor ( ADRB2) and the Glucocorticoid Receptor ( GR). This combined action targets both the acute muscular contraction pathway and the underlying chronic inflammation pathway, resulting in a dual physiological consequence.

Sustained Bronchodilation Cascade

Salmeterol binds to the ADRB2 on airway smooth muscle, triggering a signaling cascade that increases intracellular cAMP. This molecular change leads to the relaxation of the muscle cells, resulting in a sustained widening of the bronchial passages and increased capacity for gas movement.

Glucocorticoid-Mediated Anti-Inflammatory Regulation

Fluticasone Propionate binds to the intracellular GR, which then modulates gene transcription in inflammatory cells. This process suppresses the expression of pro-inflammatory mediators (like NF-kappa B signaling) while enhancing anti-inflammatory protein synthesis, influencing the structural and functional characteristics of the airway wall.

How to Use Seretide

Seretide (fluticasone propionate and salmeterol) is designed for regular, long-term maintenance treatment and is strictly administered via oral inhalation. It is available in two primary formats: a Dry Powder Inhaler (DPI) and a Metered-Dose Inhaler (MDI) aerosol. The standard frequency across all approved indications and age groups is twice daily, taken approximately 12 hours apart, and it must not be used for acute episodes of breathlessness.

---

Standard Dosing and Schedule

The appropriate dosage is selected by the healthcare provider and is typically the lowest strength required to maintain effective control. The medication is dosed based on the mu g strength of the fluticasone propionate (FP) and salmeterol (S) combination.

Indication/Population	Dose Strength (FP/S mu g)	Frequency	Dosage Unit (DPI/MDI)
Adult Asthma (ge 18 years)	100/50 to 500/50	Twice daily	One or Two inhalations
Pediatric Asthma (ge 4 years)	100/50 (DPI) or 50/25 (MDI)	Twice daily	One or Two inhalations
Adult COPD	Typically 250/50 (DPI)	Twice daily	One inhalation

---

Administration Requirements

For the MDI format, the device must be shaken immediately before each puff, and priming is required if the inhaler has not been used recently. An essential procedural condition following any inhalation is to rinse the mouth with water and spit the water out (without swallowing). If a dose is missed, the patient should proceed with the next dose at the scheduled time and not take a double dose to compensate.

Seretide: Recent Clinical Evidence

The fixed-dose combination of fluticasone propionate (an inhaled corticosteroid, ICS) and salmeterol (a long-acting beta2-agonist, LABA), marketed as Seretide, is indicated for the regular maintenance treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).

Clinical research has generally focused on evaluating the benefits of using the two agents in a single inhaler compared to using them separately or to ICS monotherapy.

---

Efficacy and Control Outcomes

Clinical trials and real-world studies in patients with asthma have shown an association with improved measures of lung function, such as Forced Expiratory Volume in 1 second ( FEV1) and Peak Expiratory Flow (PEF), compared to fluticasone propionate alone. Studies have also reported that the combination is associated with reductions in the frequency of using a rescue (reliever) inhaler and a potential decrease in asthma exacerbation rates.

For patients with COPD, evidence suggests that the combination therapy may be associated with improvements in lung function and a reduction in the frequency and severity of exacerbations.

---

Safety and Tolerability

The documented adverse event profile for the combination product is consistent with the known effects of its individual components. Common adverse events reported in clinical data include oral candidiasis (thrush), throat irritation, and headache. In patients with COPD, studies have noted an increased risk of pneumonia. The following table summarizes a selection of documented adverse events by frequency in clinical trials:

Adverse Event	Frequency	Notes
Headache, Nasopharyngitis	Very Common	Reported in clinical trials
Candidiasis (mouth/throat), Pneumonia (in COPD)	Common	May be reduced by rinsing mouth
Tremor, Palpitations, Anxiety	Uncommon	Pharmacological effects of the LABA component

Common questions about Seretide (FAQ)

---

Q: What should I do if I get an acute, severe episode of breathlessness right after using my Seretide inhaler?

A: If a sudden, severe worsening of breathing, known as paradoxical bronchospasm, occurs immediately after inhalation, regulatory information advises stopping the use of Seretide right away. Regulatory documents state that a fast-acting rescue inhaler should be used and medical attention sought immediately. This reaction requires urgent medical assessment.

---

Q: What are the serious side effects of Seretide?

A: Official product information documents several serious safety considerations. These include an increased risk of pneumonia in patients with COPD, a potential for adrenal suppression (lowered cortisol production), and the possibility of paradoxical bronchospasm. The FDA-approved labeling also contains a Boxed Warning which highlights the risk of asthma-related death associated with the LABA component, Salmeterol.

---

Q: What does the Seretide inhaler look like? (DPI vs. MDI)

A: Seretide is prepared in two main device formats: the Accuhaler, which is a dry powder inhaler (DPI), and the Evohaler, which is a metered-dose inhaler (MDI). Each device is physically distinct and comes with its own unique set of instructions for use.

---

Q: How long does it take for Seretide to start working for my symptoms?

A: Seretide is intended for long-term maintenance treatment, and clinical studies indicate that the full effect may take between four to seven days to develop. However, some initial benefits related to bronchodilation (opening of the airways) may be observed as soon as 24 hours after the first dose, according to clinical data.

---

Q: What should I do if my inhaler stops counting the remaining doses?

A: Official instructions for the device indicate that a replacement inhaler should be obtained when the dose counter displays 020. When the counter reaches 000, the inhaler is considered empty and should be stopped, as regulatory information suggests any remaining puffs may not deliver the correct or full dose.

---

Q: Does Seretide have a Black Box Warning?

A: Yes, the US FDA-approved labeling for the combined product contains a Boxed Warning. The warning pertains to the Salmeterol component, a Long-Acting Beta2-Agonist (LABA), which regulatory documents associate with an increased risk of asthma-related death.

How to Store and Dispose of Seretide?

Seretide (fluticasone propionate/salmeterol) requires specific conditions to maintain its stability and safety, as documented in official regulatory labeling.

---

Storage Requirements

Temperature and Protection: The medicine must be stored at a temperature below 30 C and kept in a dry place. It is essential to protect the product from frost (freezing), direct heat, and sunlight.

Container and Safety: The product must be stored in its original package and kept strictly out of the sight and reach of children.

---

Disposal Instructions

Canister Safety: The Metered-Dose Inhaler (MDI) canister is pressurised and must not be pierced, broken, or burned (even when empty). It should not be exposed to temperatures exceeding 50 C during storage or disposal.

Pharmaceutical Waste: Expired or unused Seretide must be returned to a pharmacist or designated local collection center. It should not be discarded via household waste or wastewater.